Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Pharmaids Pharmaceuticals Ltd (524572)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524572 NSE: Pharmaceuticals & Drugs | Small Cap | Pharmaids Pharma Share Price
₹30.27 0.63 (2.13%)
As on 23-Sep'26 11:42
Pharmaids Pharmaceuticals Ltd (524572)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524572 NSE: Pharmaceuticals & Drugs | Small Cap | Pharmaids Pharma Share Price
₹30.27 0.63 (2.13%)
As on 23-Sep'26 11:42
Key Metrics
Valuation Multiples
Market Cap
₹105 Cr.
Current Price
₹30.3
52-Week Low / High
₹26 / 66
TTM EPS
₹-1.3
TTM Sales
₹25.3 Cr.
Book Value per Share
₹14
P/E Ratio
0.00
Industry PE
54.8
Price to Book (P/B)
2.11
Lower than its 5-year historical median
Price to Sales (P/S)
4.13
Lower than its 5-year historical median
EV/EBITDA
-14.80
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-21.64%
Underperforms industry median
Return on Capital Employed (ROCE)
-15.67%
Underperforms industry median
Return on Assets (ROA)
-12.56%
Operating Profit Margin
-48.5%
Net Profit Margin
-41.5%
Gross Profit Margin
-60%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
352.99%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
32.99%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹14 Cr.
Equity
₹35.3 Cr.
Face Value
₹10
All Time Low / High
₹1.00 / 87.46
Check Before You Invest
Quality
Not GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Pharmaids Pharmaceuticals Ltd a good quality company?
Pharmaids Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Pharmaids Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Pharmaids Pharmaceuticals Ltd vs industry peers?
Pharmaids Pharmaceuticals Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Pharmaids Pharmaceuticals Ltd?
Promoters hold 32.99% of the Pharmaids Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Pharmaids Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 23.1% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pharmaids Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.6% | -29.7% | -3% | -4.5% | 1% | 1.7% | -64% | -10.9% | -7% | -12.3% | - |
| Value Creation Index ⓘ | -0.5 | -3.1 | -1.2 | -1.3 | -0.9 | -0.9 | -5.6 | -1.8 | -1.5 | -1.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1.2 | 0.5 | 0.6 | 0 | 8.6 | 3.9 | 0 | 0 | 2.3 | 10.6 | 9 |
| Sales YoY Gr. | - | -62.5% | 24.4% | -100% | NA | -53.9% | -100% | NA | 7,700% | 353% | - |
| Adj EPS ⓘ | -0.8 | -1.1 | -0.2 | 0 | 0.1 | 0.1 | -3.5 | -1.4 | -2.1 | -3.6 | -1.1 |
| YoY Gr. | - | NA | NA | NA | 200% | 55.6% | -2614.3% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 4.3 | 3.1 | 8.2 | 8.2 | 8.3 | 8.4 | 10.2 | 20.2 | 18.1 | 15.1 | 15.7 |
| Adj Net Profit ⓘ | -0.3 | -0.4 | -0.2 | 0 | 0.1 | 0.2 | -7.6 | -5 | -7.3 | -12.6 | -4 |
| Cash Flow from Ops. ⓘ | 0.3 | -0.2 | -0.1 | -0.8 | 0.4 | -0.3 | -4 | -3.4 | -7.7 | -3.5 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.6 | -4.6 | -5.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 27.4% | 4.4% | NA | 353% | ||||
| Adj EPS ⓘ | NA | -308.9% | NA | NA | ||||
| BVPSⓘ | 15.2% | 12.8% | 13.9% | -16.3% | ||||
| Share Price | 23.1% | 16.3% | -8.8% | -47.8% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -18.5 | -31.2 | -3.8 | 0.4 | 1.1 | 1.7 | -48.6 | -10.6 | -10.8 | -21.6 | -7.3 |
| Op. Profit Mgn % ⓘ | -28.6 | -86 | -18.1 | 0 | 1.3 | 3.5 | 0 | -22912.2 | -310 | -134 | -98.2 |
| Net Profit Mgn % ⓘ | -21.1 | -85.9 | -31.6 | 0 | 1.1 | 3.7 | 0 | -17806.3 | -311 | -119.2 | -41.6 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.6 | 0.4 | - |
| Working Cap Days ⓘ | 470 | 1,003 | 2,955 | 0 | 334 | 831 | 0 | 71,188 | 2,811 | 653 | 49 |
| Cash Conv. Cycle ⓘ | 214 | 359 | 345 | 0 | 3 | 12 | 0 | 14,850 | 418 | 63 | -82 |
Valuation of Pharmaids Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Sales | 4 | 0 | 15 | 19 | 28 |
| Operating Expenses ⓘ + | 4 | 10 | 27 | 32 | 41 |
| Operating Profit ⓘ | 0 | -10 | -12 | -13 | -14 |
| Operating Profit Margin (%) | 3.5% | - | -81.9% | -65.5% | -48.5% |
| Other Income ⓘ + | 0 | 0 | 1 | 0 | 0 |
| Interest ⓘ | 0 | 0 | 2 | 2 | 4 |
| Depreciation ⓘ | 0 | 0 | 2 | 2 | 2 |
| Profit Before Tax ⓘ | 0 | -10 | -16 | -17 | -16 |
| Tax ⓘ | -0 | -2 | -4 | -4 | -5 |
| Profit After Tax | 0 | -8 | -12 | -14 | -12 |
| PAT Margin (%) | 3.7% | - | -78.4% | -69.4% | -41.5% |
| Adjusted EPS (₹) | 0.1 | -3.5 | -2.3 | -3.1 | -3.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 9 | 22 | 72 | 59 | 48 | ||||||
| Debt + | 0 | 0 | 5 | 35 | 21 | ||||||
| Minority Interest | 0 | 0 | -2 | -4 | -0 | ||||||
| Trade Payables | 2 | 2 | 5 | 16 | 3 | ||||||
| Others Liabilities ⓘ | -0 | -2 | 4 | 3 | 4 | ||||||
| Total Liabilities ⓘ | 11 | 22 | 85 | 109 | 75 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 0 | 0 | 63 | 77 | 54 | ||||||
| CWIP ⓘ | 0 | 2 | 7 | 5 | 6 | ||||||
| Investments ⓘ | 0 | 3 | 0 | 0 | 0 | ||||||
| Inventories | 1 | 0 | 4 | 12 | 0 | ||||||
| Trade Receivables | 1 | 2 | 3 | 3 | 3 | ||||||
| Cash Equivalents | 0 | 13 | 5 | 1 | 0 | ||||||
| Others Assets ⓘ | 8 | 2 | 3 | 12 | 11 | ||||||
| Total Assets ⓘ | 11 | 22 | 85 | 109 | 75 | ||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -0 | -4 | -11 | -15 | -4 |
| Cash Flow From Investing Activity ⓘ + | 0 | -5 | -75 | -12 | 23 |
| Cash Flow From Financing Activity ⓘ + | 0 | 21 | 78 | 23 | -20 |
| Net Cash Flow ⓘ | 0 | 12 | -8 | -4 | -1 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 1.67 | -49.28 | -25.19 | -20.56 | -21.64 | |||||
| ROCE (%) | 1.65 | -63.88 | -28.16 | -17.65 | -15.67 | |||||
| Asset Turnover Ratio | 0.37 | 0 | 0.28 | 0.2 | 0.3 | |||||
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 124 | 0 | 57.20 | 54.50 | 42.90 | |||||
| Inventory Days | 82.30 | 0 | 86.70 | 148 | 82.40 | |||||
| Payable Days | 235.70 | 861.30 | 111.40 | 305 | 203.20 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Pharmaids Pharmaceuticals Ltd FAQs
The current trading price of Pharmaids Pharma on 23-Sep-2026 11:42 is ₹30.27.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Pharmaids Pharma stood at ₹104.5 Cr
The latest P/E ratio of Pharmaids Pharma as of 22-Sep-2026 is 0.00.
The latest P/B ratio of Pharmaids Pharma as of 22-Sep-2026 is 1.88.
The 52-week high of Pharmaids Pharma is ₹66.00 and the 52-week low is ₹25.60.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pharmaids Pharma is ₹9.49 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Pharmaids Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Pharmaids Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Pharmaids Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Pharmaids Pharmaceuticals Ltd
Pharmaids Pharmaceuticals Limited Incorporated in the year 1989 at Hyderabad (Telangana, India). The company is suppliers of Quality Grade range of Specialty chemicals, Skin care, Hospital care and Generic products in the areas of Orthopedic, Neuro and Gastro etc. Its technical team uses quality proven chemical compounds and standard processing methods maintaining proper hygienic standards. Its professionals strive to offer best quality and high purity to attain maximum client's satisfaction. The company’s offered product range is highly acknowledged in the market for its precise composition long shelf life, hygienic processing techniques, premium quality and high purity.
Business area of the company
The Company is engaged in the business of Trading and Manufacturing of Generics, Bulk Drugs and Intermediaries, etc.
Products
- Speciality Chemicals
- Skin Care Products
- Hospital Care Products
- Generics
You have 43 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
